149 related articles for article (PubMed ID: 22584853)
1. [Serous and non-serous ovarian carcinoma: histological tumor type as related to the grade of differentiation and disease prognosis].
Ferreira PA; Sallum LF; Sarian LO; Andrade LA; Derchain S
Rev Bras Ginecol Obstet; 2012 May; 34(5):196-202. PubMed ID: 22584853
[TBL] [Abstract][Full Text] [Related]
2. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
3. Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015.
Krugmann J; Schwarz CL; Melcher B; Sterlacci W; Ozalinskaite A; Lermann J; Agaimy A; Vieth M
Arch Gynecol Obstet; 2019 Feb; 299(2):515-523. PubMed ID: 30415435
[TBL] [Abstract][Full Text] [Related]
4. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
[TBL] [Abstract][Full Text] [Related]
5. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
7. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
8. Distribution and case-fatality ratios by cell-type for ovarian carcinomas: a 22-year series of 562 patients with uniform current histological classification.
Seidman JD; Vang R; Ronnett BM; Yemelyanova A; Cosin JA
Gynecol Oncol; 2015 Feb; 136(2):336-40. PubMed ID: 25528497
[TBL] [Abstract][Full Text] [Related]
9. CD56 (Neural Cell Adhesion Molecule) Expression in Ovarian Carcinomas: Association With High-Grade and Advanced Stage But Not With Neuroendocrine Differentiation.
Bösmüller HC; Wagner P; Pham DL; Fischer AK; Greif K; Beschorner C; Sipos B; Fend F; Staebler A
Int J Gynecol Cancer; 2017 Feb; 27(2):239-245. PubMed ID: 27984374
[TBL] [Abstract][Full Text] [Related]
10. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
[TBL] [Abstract][Full Text] [Related]
11. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
[TBL] [Abstract][Full Text] [Related]
12. HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.
Gagné A; Têtu B; Orain M; Turcotte S; Plante M; Grégoire J; Renaud MC; Bairati I; Trudel D
Diagn Pathol; 2018 Aug; 13(1):57. PubMed ID: 30131069
[TBL] [Abstract][Full Text] [Related]
13. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
[TBL] [Abstract][Full Text] [Related]
14. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Pietzner K; Dietel M; Sehouli J; Darb-Esfahani S
Virchows Arch; 2015 Mar; 466(3):333-42. PubMed ID: 25522951
[TBL] [Abstract][Full Text] [Related]
16. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
[TBL] [Abstract][Full Text] [Related]
17. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
Hannibal CG; Vang R; Junge J; Frederiksen K; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Jan; 144(1):174-180. PubMed ID: 27836204
[TBL] [Abstract][Full Text] [Related]
18. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas.
Usach I; Blansit K; Chen LM; Ueda S; Brooks R; Kapp DS; Chan JK
Am J Obstet Gynecol; 2015 Feb; 212(2):188.e1-6. PubMed ID: 25149685
[TBL] [Abstract][Full Text] [Related]
19. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
[TBL] [Abstract][Full Text] [Related]
20. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]